|566.96||-8.08||-1.41%||Vol 78.61K||1Y Perf 12.38%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||566.67||Analyst Rating||Strong Buy 1.33|
|Potential %||-0.05||Finscreener Ranking||★ 41.23|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★ 39.25|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★+ 55.10|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★ 31.31|
|Price Range Ratio 52W %||78.25||Earnings Rating||Sell|
|Market Cap||8.54B||Earnings Date||25th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||4.92|
|EPS Growth Next 5 Years %||8.90|
|Avg. Weekly Volume||67.01K|
|Avg. Monthly Volume||81.33K|
|Avg. Quarterly Volume||73.27K|
Chemed Corp (NYSE: CHE) stock closed at 575.04 per share at the end of the most recent trading day (a -0.51% change compared to the prior day closing price) with a volume of 71.22K shares and market capitalization of 8.54B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 15544 people. Chemed Corp CEO is Kevin J. Mcnamara.
The one-year performance of Chemed Corp stock is 12.38%, while year-to-date (YTD) performance is 12.66%. CHE stock has a five-year performance of 84.22%. Its 52-week range is between 481.99 and 590.58, which gives CHE stock a 52-week price range ratio of 78.25%
Chemed Corp currently has a PE ratio of 29.10, a price-to-book (PB) ratio of 10.33, a price-to-sale (PS) ratio of 4.62, a price to cashflow ratio of 27.90, a PEG ratio of 3.27, a ROA of 21.20%, a ROC of 28.04% and a ROE of 37.94%. The company’s profit margin is 11.80%, its EBITDA margin is 19.10%, and its revenue ttm is $1.59 Billion , which makes it $106.81 revenue per share.
Of the last four earnings reports from Chemed Corp, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.92 for the next earnings report. Chemed Corp’s next earnings report date is -.
The consensus rating of Wall Street analysts for Chemed Corp is Strong Buy (1.33), with a target price of $566.67, which is -0.05% compared to the current price. The earnings rating for Chemed Corp stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chemed Corp has a dividend yield of 0.31% with a dividend per share of $1.52 and a payout ratio of 6.00%.
Chemed Corp has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.92, ATR14 : 8.78, CCI20 : -27.17, Chaikin Money Flow : -0.10, MACD : 10.94, Money Flow Index : 36.30, ROC : -1.32, RSI : 59.12, STOCH (14,3) : 8.80, STOCH RSI : 0.00, UO : 36.40, Williams %R : -91.20), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chemed Corp in the last 12-months were: Grace Patrick (Sold 294 shares of value $160 007 ), Judkins Brian (Option Excercise at a value of $302 375), Lee Spencer (Option Excercise at a value of $419 823), Lee Spencer (Sold 2 217 shares of value $1 290 275 ), Mcnamara Kevin (Option Excercise at a value of $2 186 684), Mcnamara Kevin (Sold 14 000 shares of value $7 594 210 ), Tom Hutton (Option Excercise at a value of $167 929), Walsh George (Buy at a value of $2 037), Westfall Nicholas (Option Excercise at a value of $630 507), Westfall Nicholas (Sold 14 000 shares of value $7 480 631 ), Williams David Patrick (Sold 0 shares of value $0 ), Williams David Patrick (Sold 21 000 shares of value $12 182 715 ), Witzeman Michael (Option Excercise at a value of $344 615)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.